Experience
Sandoz, Inc.
Pharmacyclics LLC; Janssen Biotech, Inc.
Represented patent owner in inter partes review (IPR) challenge related to Imbruvica® (ibrutinib) for the treatment of chronic graft versus host disease.
Sandoz, Inc. v. Pharmacyclics LLC; Janssen Biotech, Inc., IPR2019-00865, PTAB, Judges Cotta, Snedden, Mitchell
Sandoz Inc. v. Boehringer Ingelheim International GmbH et al.
Boehringer Ingelheim International GmbH et al.
Coalition for Affordable Drugs IV LLC v. Pharmacyclics, Inc.
AbbVie Inc.; Janssen Biotech, Inc.; Pharmacyclics LLC; Pharmacyclics, Inc.
LG Electronics, Inc. et al. v. Cellular Communications Equipment LLC
LG Electronics, Inc. et al.
Sequenom, Inc. et al
Mylan Pharmaceuticals Inc. et al. v. Biogen MA Inc. et al.
Biogen MA Inc. et al.
Uniloc USA, Inc. et al. v. Motorola Mobility LLC et al.
Motorola Mobility LLC et al.
BioDelivery Sciences International, Inc. et al. v. Alvogen PB Research & Development LLC et al.
BioDelivery Sciences International, Inc. et al.
CardioNet LLC et al. v. InfoBionic, Inc.
CardioNet LLC et al.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.